Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease Atherosclerosis As a Major Player in the Natural Course of NAFLD

Autores
Lonardo, Amedeo; Sookoian, Silvia Cristina; Chonchol, Michel; Loria, Paola; Targher, Giovanni
Año de publicación
2013
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Non-alcoholic fatty liver disease (NAFLD) encompasses pure steatosis through nonalcoholic steatohepatitis (NASH) and is the most common cause of chronic liver disease in Western countries. NASH is a progressive liver disease that increases the risk of cirrhosis and end-stage liver disease. Interestingly, the global health risk of NAFLD is not confined to the liver. Compared with those without NAFLD, patients with NAFLD exhibit not only increased liver-related complications and liver-related mortality but also increased risk of developing type 2 diabetes, cardiovascular disease (CVD) and chronic kidney disease, increased risk of post-operative complications after major liver surgery, and increased risk of developing certain malignancies, including primary liver cancer and colorectal cancer. In this review, we discuss the current evidence linking NAFLD with the risk of CVD in the setting of the more complex scenario of other hepatic and extra-hepatic complications that may occur during the natural course of NAFLD. Moreover, we provide a brief description of the putative biological mechanisms underlying such complications, particular emphasis being given to CVD. We conclude that NAFLD is a complex health problem with implications far beyond the liver. Hence, it may cause a significant global health burden and the assistance of patients with NAFLD impacts on the work of physicians from many different medical specialties.
Fil: Lonardo, Amedeo. University of Modena ; Italia
Fil: Sookoian, Silvia Cristina. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Investigaciones Medicas; Argentina. Universidad de Buenos Aires; Argentina
Fil: Chonchol, Michel. University of Colorado Denver; Estados Unidos
Fil: Loria, Paola. University of Modena; Italia
Fil: Targher, Giovanni. University and Azienda Ospedaliera Universitaria Integrata of Verona; Italia
Materia
Fatty Liver
Cardiovascular Risk
Nash
Atherosclerosis
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/11563
Acceder
id CONICETDig_e0ce31f0b0aa832a5d730ffb05b29824
oai_identifier_str oai:ri.conicet.gov.ar:11336/11563
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease Atherosclerosis As a Major Player in the Natural Course of NAFLDLonardo, AmedeoSookoian, Silvia CristinaChonchol, MichelLoria, PaolaTargher, GiovanniFatty LiverCardiovascular RiskNashAtherosclerosishttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Non-alcoholic fatty liver disease (NAFLD) encompasses pure steatosis through nonalcoholic steatohepatitis (NASH) and is the most common cause of chronic liver disease in Western countries. NASH is a progressive liver disease that increases the risk of cirrhosis and end-stage liver disease. Interestingly, the global health risk of NAFLD is not confined to the liver. Compared with those without NAFLD, patients with NAFLD exhibit not only increased liver-related complications and liver-related mortality but also increased risk of developing type 2 diabetes, cardiovascular disease (CVD) and chronic kidney disease, increased risk of post-operative complications after major liver surgery, and increased risk of developing certain malignancies, including primary liver cancer and colorectal cancer. In this review, we discuss the current evidence linking NAFLD with the risk of CVD in the setting of the more complex scenario of other hepatic and extra-hepatic complications that may occur during the natural course of NAFLD. Moreover, we provide a brief description of the putative biological mechanisms underlying such complications, particular emphasis being given to CVD. We conclude that NAFLD is a complex health problem with implications far beyond the liver. Hence, it may cause a significant global health burden and the assistance of patients with NAFLD impacts on the work of physicians from many different medical specialties.Fil: Lonardo, Amedeo. University of Modena ; ItaliaFil: Sookoian, Silvia Cristina. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Investigaciones Medicas; Argentina. Universidad de Buenos Aires; ArgentinaFil: Chonchol, Michel. University of Colorado Denver; Estados UnidosFil: Loria, Paola. University of Modena; ItaliaFil: Targher, Giovanni. University and Azienda Ospedaliera Universitaria Integrata of Verona; ItaliaBentham Science Publishers2013-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/11563Lonardo, Amedeo; Sookoian, Silvia Cristina; Chonchol, Michel; Loria, Paola; Targher, Giovanni; Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease Atherosclerosis As a Major Player in the Natural Course of NAFLD; Bentham Science Publishers; Current Pharmaceutical Design.; 19; 29; 2-2013; 5177 - 51921381-6128enginfo:eu-repo/semantics/altIdentifier/url/http://www.eurekaselect.com/112995info:eu-repo/semantics/altIdentifier/doi/10.2174/1381612811319290003info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:47:50Zoai:ri.conicet.gov.ar:11336/11563instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:47:50.473CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease Atherosclerosis As a Major Player in the Natural Course of NAFLD
title Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease Atherosclerosis As a Major Player in the Natural Course of NAFLD
spellingShingle Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease Atherosclerosis As a Major Player in the Natural Course of NAFLD
Lonardo, Amedeo
Fatty Liver
Cardiovascular Risk
Nash
Atherosclerosis
title_short Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease Atherosclerosis As a Major Player in the Natural Course of NAFLD
title_full Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease Atherosclerosis As a Major Player in the Natural Course of NAFLD
title_fullStr Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease Atherosclerosis As a Major Player in the Natural Course of NAFLD
title_full_unstemmed Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease Atherosclerosis As a Major Player in the Natural Course of NAFLD
title_sort Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease Atherosclerosis As a Major Player in the Natural Course of NAFLD
dc.creator.none.fl_str_mv Lonardo, Amedeo
Sookoian, Silvia Cristina
Chonchol, Michel
Loria, Paola
Targher, Giovanni
author Lonardo, Amedeo
author_facet Lonardo, Amedeo
Sookoian, Silvia Cristina
Chonchol, Michel
Loria, Paola
Targher, Giovanni
author_role author
author2 Sookoian, Silvia Cristina
Chonchol, Michel
Loria, Paola
Targher, Giovanni
author2_role author
author
author
author
dc.subject.none.fl_str_mv Fatty Liver
Cardiovascular Risk
Nash
Atherosclerosis
topic Fatty Liver
Cardiovascular Risk
Nash
Atherosclerosis
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Non-alcoholic fatty liver disease (NAFLD) encompasses pure steatosis through nonalcoholic steatohepatitis (NASH) and is the most common cause of chronic liver disease in Western countries. NASH is a progressive liver disease that increases the risk of cirrhosis and end-stage liver disease. Interestingly, the global health risk of NAFLD is not confined to the liver. Compared with those without NAFLD, patients with NAFLD exhibit not only increased liver-related complications and liver-related mortality but also increased risk of developing type 2 diabetes, cardiovascular disease (CVD) and chronic kidney disease, increased risk of post-operative complications after major liver surgery, and increased risk of developing certain malignancies, including primary liver cancer and colorectal cancer. In this review, we discuss the current evidence linking NAFLD with the risk of CVD in the setting of the more complex scenario of other hepatic and extra-hepatic complications that may occur during the natural course of NAFLD. Moreover, we provide a brief description of the putative biological mechanisms underlying such complications, particular emphasis being given to CVD. We conclude that NAFLD is a complex health problem with implications far beyond the liver. Hence, it may cause a significant global health burden and the assistance of patients with NAFLD impacts on the work of physicians from many different medical specialties.
Fil: Lonardo, Amedeo. University of Modena ; Italia
Fil: Sookoian, Silvia Cristina. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Investigaciones Medicas; Argentina. Universidad de Buenos Aires; Argentina
Fil: Chonchol, Michel. University of Colorado Denver; Estados Unidos
Fil: Loria, Paola. University of Modena; Italia
Fil: Targher, Giovanni. University and Azienda Ospedaliera Universitaria Integrata of Verona; Italia
description Non-alcoholic fatty liver disease (NAFLD) encompasses pure steatosis through nonalcoholic steatohepatitis (NASH) and is the most common cause of chronic liver disease in Western countries. NASH is a progressive liver disease that increases the risk of cirrhosis and end-stage liver disease. Interestingly, the global health risk of NAFLD is not confined to the liver. Compared with those without NAFLD, patients with NAFLD exhibit not only increased liver-related complications and liver-related mortality but also increased risk of developing type 2 diabetes, cardiovascular disease (CVD) and chronic kidney disease, increased risk of post-operative complications after major liver surgery, and increased risk of developing certain malignancies, including primary liver cancer and colorectal cancer. In this review, we discuss the current evidence linking NAFLD with the risk of CVD in the setting of the more complex scenario of other hepatic and extra-hepatic complications that may occur during the natural course of NAFLD. Moreover, we provide a brief description of the putative biological mechanisms underlying such complications, particular emphasis being given to CVD. We conclude that NAFLD is a complex health problem with implications far beyond the liver. Hence, it may cause a significant global health burden and the assistance of patients with NAFLD impacts on the work of physicians from many different medical specialties.
publishDate 2013
dc.date.none.fl_str_mv 2013-02
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/11563
Lonardo, Amedeo; Sookoian, Silvia Cristina; Chonchol, Michel; Loria, Paola; Targher, Giovanni; Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease Atherosclerosis As a Major Player in the Natural Course of NAFLD; Bentham Science Publishers; Current Pharmaceutical Design.; 19; 29; 2-2013; 5177 - 5192
1381-6128
url http://hdl.handle.net/11336/11563
identifier_str_mv Lonardo, Amedeo; Sookoian, Silvia Cristina; Chonchol, Michel; Loria, Paola; Targher, Giovanni; Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease Atherosclerosis As a Major Player in the Natural Course of NAFLD; Bentham Science Publishers; Current Pharmaceutical Design.; 19; 29; 2-2013; 5177 - 5192
1381-6128
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.eurekaselect.com/112995
info:eu-repo/semantics/altIdentifier/doi/10.2174/1381612811319290003
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Bentham Science Publishers
publisher.none.fl_str_mv Bentham Science Publishers
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842268884990689280
score 13.13397

Publicaciones similares